TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Components: The large molecular-weight biological unit is proteins, oligopeptides, polypeptides, DNAs, RNAs, DNA plasmids, siRNAs or anti-sense molecules.    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Pharmacological Compound: The pharmacological compounds (C1) and (C2) are antiinflammatory, antineoplastic, immunosuppressant, antirestenotic or antithrombotic compounds. When the compound (C1) is an antirestenotic compound, the compound (C2) is an antithrombotic or an antiinflammatory compound. Further compound (C1) is rapamycin or its derivative or analog, phosphatidylinositol 3 kinase inhibitor (PI3 kinase inhibitor), taxane or large molecular-weight biological unit. The rapamycin or its derivative or analog is everolimus, biolimus, zotarolimus, pimecrolimus, or tacrolimus. The PI3 kinase inhibitor is wortmannin and its derivative or analog selected from PX 867, PX 866, viridiol, virudin or demethoxyviridin. The taxane is docetaxel, paclitaxel or its derivative or analog.    TECHNOLOGY FOCUS - POLYMERS - Preferred Article: The drug-eluting article further comprises a third polymeric layer over the second polymeric layer; and additional polymeric layers over the third polymeric layer. Preferred Components: The third polymeric layer comprises at least one third biocompatible polymer (P3) having a degradability higher than that of (P1) and (P2). The third polymeric layer comprises pharmacological compound that is same or different from the pharmacological compound contained in the first and/or second polymeric layer and further comprises compound (C1) encapsulated in polymer (P3) at a concentration that is different from the concentration of compound (C1) in the first polymeric layer. The biocompatible polymers (P1), (P2) and (P3) are biostable as well as biodegradable. The biocompatible polymer (P2) is more hydrophilic; has lower molecular weight and crystallinity than polymer (P1) and encapsulates a pharmacological compound that is same or different from compound (C1). The pharmacological compound present in polymer (P2) is at a higher concentration than that of polymer (P1). The biocompatible polymer (P2) is less hydrophobic and has a faster drug release profile than polymer (P1). The biocompatible polymers (P1),(P2) and (P3) are poly(ethylene vinyl-acetate), poly(alkyl methacrylate), polylactic acid (PLA), polyglycolid acid (PGA), copolymers of lactic acid and glycolic acid (PLGA), polycaprolactone, polyphosphoester, poly-orthoester, poly(hydroxy butyrate), poly(diaxanone), poly(hydroxy valerate), poly(hydroxy butyrate-co-valerate), poly(glycolide-co-trimethylene carbonate), polyanhydrides, polyphosphoester, poly(ester-amide), polyphosphoeser, polyphosphazene, poly(phosphoester-urethane), poly(amino acids), polycyanoacrylates, fibrin, fibrinogen, cellulose, starch, collagen and/or hyaluronic acid. The second polymeric layer further comprises a second different pharmacological compound (C2) encapsulated in polymer (P2) and further comprises compound (C1). ACTIVITY - None given.    MECHANISM OF ACTION - None given.    EXAMPLE - No suitable example given.